SLC5A2 and hydrops fetalis: Noteworthy differences in the utilization of HF treatments were observed, with the surviving cohort demonstrating higher percentages of beta-blocker (BB), renin-angiotensin system inhibitor (RASi), and sodium-glucose cotransporter-2 inhibitor (SGLT-2i) use.